CHI3L1 and myeloid sarcoma: Conventional anti-inflammatory treatment for MS with powerful drugs such as natalizumab and mitoxantrone was also followed by a lowering of YKL-40 concentrations in CSF but not in serum, indicating an intrathecal inflammatory source of CSF YKL-40 [27].